Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1987 Jan;84(2):570–574. doi: 10.1073/pnas.84.2.570

Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection.

W Henle, G Henle, J Andersson, I Ernberg, G Klein, C A Horwitz, G Marklund, L Rymo, C Wellinder, S E Straus
PMCID: PMC304252  PMID: 3025881

Abstract

Five distinct Epstein-Barr virus (EBV)-determined nuclear antigens (EBNA-1 to EBNA-5) were recently identified. Antibody responses to these antigens could conceivably differ, and thus prove of serodiagnostic value, in EBV-associated disease processes. As a first step, murine or human cell lines transfected with appropriate EBV DNA fragments and stably expressing either EBNA-1 or EBNA-2 were used to determine the frequency and time of emergence of antibodies to these two antigens in the course of acute and chronic infectious mononucleosis (IM) and to assess their titers in so-called chronic active EBV infections. Following IM, antibodies to EBNA-2 arose first and, after reaching peak titers, declined again in time to lower persistent or even nondetectable levels. Antibodies to EBNA-1 emerged several weeks or months after anti-EBNA-2 and gradually attained the titers at which they persisted indefinitely. The ratios between the anti-EBNA-1 and anti-EBNA-2 titers therefore were generally well below 1.0 during the first 6-12 months after IM and turned to well above 1.0 during the second year. In clear cases of chronic IM, the inversion of this ratio was delayed or prevented. In the less well-defined chronic EBV infections, low ratios were observed in only some of the patients. Because many of these illnesses were not ushered in by a proven IM and often showed EBV-specific antibody profiles within the normally expected range, a causal role of the virus in these cases remains doubtful.

Full text

PDF
570

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson J., Britton S., Ernberg I., Andersson U., Henle W., Sköldenberg B., Tisell A. Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. J Infect Dis. 1986 Feb;153(2):283–290. doi: 10.1093/infdis/153.2.283. [DOI] [PubMed] [Google Scholar]
  2. Dillner J., Kallin B., Alexander H., Ernberg I., Uno M., Ono Y., Klein G., Lerner R. A. An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A. 1986 Sep;83(17):6641–6645. doi: 10.1073/pnas.83.17.6641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dillner J., Kallin B., Ehlin-Henriksson B., Rymo L., Henle W., Henle G., Klein G. The Epstein-Barr virus determined nuclear antigen is composed of at least three different antigens. Int J Cancer. 1986 Feb 15;37(2):195–200. doi: 10.1002/ijc.2910370205. [DOI] [PubMed] [Google Scholar]
  4. Dillner J., Kallin B., Ehlin-Henriksson B., Timar L., Klein G. Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA. Int J Cancer. 1985 Mar 15;35(3):359–366. doi: 10.1002/ijc.2910350312. [DOI] [PubMed] [Google Scholar]
  5. Dillner J., Kallin B., Klein G., Jörnvall H., Alexander H., Lerner R. Antibodies against synthetic peptides react with the second Epstein-Barr virus-associated nuclear antigen. EMBO J. 1985 Jul;4(7):1813–1818. doi: 10.1002/j.1460-2075.1985.tb03855.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dillner J., Sternås L., Kallin B., Alexander H., Ehlin-Henriksson B., Jörnvall H., Klein G., Lerner R. Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A. 1984 Aug;81(15):4652–4656. doi: 10.1073/pnas.81.15.4652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. DuBois R. E., Seeley J. K., Brus I., Sakamoto K., Ballow M., Harada S., Bechtold T. A., Pearson G., Purtilo D. T. Chronic mononucleosis syndrome. South Med J. 1984 Nov;77(11):1376–1382. doi: 10.1097/00007611-198411000-00007. [DOI] [PubMed] [Google Scholar]
  8. Edson C. M., Cohen L. K., Henle W., Strominger J. L. An unusually high-titer human anti-Epstein Barr virus (EBV) serum and its use in the study of EBV-specific proteins synthesized in vitro and in vivo. J Immunol. 1983 Feb;130(2):919–924. [PubMed] [Google Scholar]
  9. Henie G., Henle W., Horwitz C. A. Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis. J Infect Dis. 1974 Sep;130(3):231–239. doi: 10.1093/infdis/130.3.231. [DOI] [PubMed] [Google Scholar]
  10. Henle W., Henle G. E., Horwitz C. A. Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol. 1974 Sep;5(5):551–565. doi: 10.1016/s0046-8177(74)80006-7. [DOI] [PubMed] [Google Scholar]
  11. Henle W., Henle G. Epstein-Barr virus-specific serology in immunologically compromised individuals. Cancer Res. 1981 Nov;41(11 Pt 1):4222–4225. [PubMed] [Google Scholar]
  12. Hennessy K., Fennewald S., Kieff E. A third viral nuclear protein in lymphoblasts immortalized by Epstein-Barr virus. Proc Natl Acad Sci U S A. 1985 Sep;82(17):5944–5948. doi: 10.1073/pnas.82.17.5944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hennessy K., Kieff E. A second nuclear protein is encoded by Epstein-Barr virus in latent infection. Science. 1985 Mar 8;227(4691):1238–1240. doi: 10.1126/science.2983420. [DOI] [PubMed] [Google Scholar]
  14. Hennessy K., Kieff E. One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. Proc Natl Acad Sci U S A. 1983 Sep;80(18):5665–5669. doi: 10.1073/pnas.80.18.5665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Horwitz C. A., Henle W., Henle G., Rudnick H., Latts E. Long-term serological follow-up of patients for Epstein-Barr virus after recovery from infectious mononucleosis. J Infect Dis. 1985 Jun;151(6):1150–1153. doi: 10.1093/infdis/151.6.1150. [DOI] [PubMed] [Google Scholar]
  16. Jones J. F., Ray C. G., Minnich L. L., Hicks M. J., Kibler R., Lucas D. O. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med. 1985 Jan;102(1):1–7. doi: 10.7326/0003-4819-102-1-. [DOI] [PubMed] [Google Scholar]
  17. Kallin B., Dillner J., Ernberg I., Ehlin-Henriksson B., Rosén A., Henle W., Henle G., Klein G. Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1499–1503. doi: 10.1073/pnas.83.5.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Marklund G., Ernberg I., Lundberg C., Henle W., Henle G. Differences in EBV-specific antibody patterns at onset of infectious mononucleosis. Scand J Infect Dis. 1986;18(1):25–32. doi: 10.3109/00365548609032302. [DOI] [PubMed] [Google Scholar]
  19. Marklund G., Henle W., Henle G., Ernberg I. IgA antibodies to Epstein-Barr virus in infectious mononucleosis. Scand J Infect Dis. 1986;18(2):111–119. doi: 10.3109/00365548609032316. [DOI] [PubMed] [Google Scholar]
  20. Masucci G., Mellstedt H., Masucci M. G., Szigeti R., Ernberg I., Björkholm M., Tsukuda K., Henle G., Henle W., Pearson G. Immunological characterization of Hodgkin's and non-Hodgkin's lymphoma patients with high antibody titers against Epstein-Barr virus-associated antigens. Cancer Res. 1984 Mar;44(3):1288–1300. [PubMed] [Google Scholar]
  21. Menezes J., Leibold W., Klein G. Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction. Exp Cell Res. 1975 May;92(2):478–484. doi: 10.1016/0014-4827(75)90404-8. [DOI] [PubMed] [Google Scholar]
  22. Miller G., Grogan E., Fischer D. K., Niederman J. C., Schooley R. T., Henle W., Lenoir G., Liu C. R. Antibody responses to two Epstein-Barr virus nuclear antigens defined by gene transfer. N Engl J Med. 1985 Mar 21;312(12):750–755. doi: 10.1056/NEJM198503213121204. [DOI] [PubMed] [Google Scholar]
  23. Mueller-Lantzsch N., Lenoir G. M., Sauter M., Takaki K., Béchet J. M., Kuklik-Roos C., Wunderlich D., Bornkamm G. W. Identification of the coding region for a second Epstein-Barr virus nuclear antigen (EBNA 2) by transfection of cloned DNA fragments. EMBO J. 1985 Jul;4(7):1805–1811. doi: 10.1002/j.1460-2075.1985.tb03854.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Niederman J. C., Miller G. Kinetics of the antibody response to BamHI-K nuclear antigen in uncomplicated infectious mononucleosis. J Infect Dis. 1986 Aug;154(2):346–349. doi: 10.1093/infdis/154.2.346. [DOI] [PubMed] [Google Scholar]
  25. Reedman B. M., Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer. 1973 May;11(3):499–520. doi: 10.1002/ijc.2910110302. [DOI] [PubMed] [Google Scholar]
  26. Rymo L., Klein G., Ricksten A. Expression of a second Epstein-Barr virus-determined nuclear antigen in mouse cells after gene transfer with a cloned fragment of the viral genome. Proc Natl Acad Sci U S A. 1985 May;82(10):3435–3439. doi: 10.1073/pnas.82.10.3435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Schooley R. T., Carey R. W., Miller G., Henle W., Eastman R., Mark E. J., Kenyon K., Wheeler E. O., Rubin R. H. Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. Ann Intern Med. 1986 May;104(5):636–643. doi: 10.7326/0003-4819-104-5-636. [DOI] [PubMed] [Google Scholar]
  28. Sixbey J. W., Nedrud J. G., Raab-Traub N., Hanes R. A., Pagano J. S. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med. 1984 May 10;310(19):1225–1230. doi: 10.1056/NEJM198405103101905. [DOI] [PubMed] [Google Scholar]
  29. Straus S. E., Tosato G., Armstrong G., Lawley T., Preble O. T., Henle W., Davey R., Pearson G., Epstein J., Brus I. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med. 1985 Jan;102(1):7–16. doi: 10.7326/0003-4819-102-1-7. [DOI] [PubMed] [Google Scholar]
  30. Strnad B. C., Schuster T. C., Hopkins R. F., 3rd, Neubauer R. H., Rabin H. Identification of an Epstein-Barr virus nuclear antigen by fluoroimmunoelectrophoresis and radioimmunoelectrophoresis. J Virol. 1981 Jun;38(3):996–1004. doi: 10.1128/jvi.38.3.996-1004.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Summers W. P., Grogan E. A., Shedd D., Robert M., Liu C. R., Miller G. Stable expression in mouse cells of nuclear neoantigen after transfer of a 3.4-megadalton cloned fragment of Epstein-Barr virus DNA. Proc Natl Acad Sci U S A. 1982 Sep;79(18):5688–5692. doi: 10.1073/pnas.79.18.5688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Yates J., Warren N., Reisman D., Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A. 1984 Jun;81(12):3806–3810. doi: 10.1073/pnas.81.12.3806. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES